|Bid||100.26 x 100|
|Ask||109.00 x 100|
|Day's Range||104.47 - 108.06|
|52 Week Range||92.65 - 136.95|
|PE Ratio (TTM)||-19.12|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||148.13|
Do you have a few moments? Interested in marijuana stocks? Here's a brief look at the marijuana stocks available on the market.
Could cannabis hold the key to lowering or eliminating opioid-related deaths?
USA News Group -To capture big gains prior to wide adoption and legalization in the marijuana space may require thinking a little outside the box or perhaps outside your geographical comfort zone. Many top pot stocks are on the rise and up hundreds of percent as the cannabis market is booming. The first obvious move is to focus on Canadian companies.
NEW YORK, NY / ACCESSWIRE / October 4, 2017 / All three of the U.S. major indexes reached new records for the second consecutive session as recent economic data continues to support a healthy U.S. economy. ...
Marijuana can reduce seizures in epilepsy patients, but Zogenix's ZX008 might control seizures even better.
Zogenix rocketed to its highest point in nearly seven years Monday after it announced a public offering of 4.3 million shares.
After reporting positive phase 3 results for its drug for Dravet syndrome last week, management announced a dilutive stock offering today to raise more capital.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to GW Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to GWPH-US. Comparing the performance and risk of GW Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
NEW YORK, NY / ACCESSWIRE / October 2, 2017 / In the biotech world, it's often a race between pharma companies to get to the finish line with their drug candidates faster than others. Shares of GW Pharmaceuticals ...
Zogenix's low-dose fenfluramine may lower the rate of seizures in Dravet syndrome patients by more than GW Pharma's Epidiolex.
Zogenix rocketed Friday after reporting Phase 3 data of a seizure drug that widely topped earlier results from rival GW Pharma.
On Friday, shares of pharmaceutical company Zogenix Inc. (ZGNX) are skyrocketing after it announced positive results from its first Phase 3 study of ZX008, a drug used to treat the rare epilepsy form Dravet Syndrome.
The Emeryville, Calif.-based firm said its first Phase 3 study of ZX008 in Dravet syndrome achieved its primary endpoint. Dravet syndrome is a form of epilepsy.